Endpoints 11 winner MediLink Therapeutics: China startup helps power the ADC renaissance

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Curcumin shows promise in preventing and treating oral submucosal fibrosis

Researchers explore the mechanisms, therapeutic potential, and clinical applications of curcumin in preventing and treating oral submucosal fibrosis.

October 30, 2024

GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial – Pharmaceutical Technology

GSK anticipates regulatory submission for Europe and Canada in 2025, as per a previous earnings report. Image credit: Shutterstock / OleksSH. GSK’s asthma drug Nucala

September 6, 2024

Novel Anti-CD40L Antibody Slows New Brain Lesions in Relapsing MS

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

February 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.